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The use of next-generation sequencing enables a rapid analysis of many genes associated
with sudden cardiac death in diseases like Brugada Syndrome. Genetic variation is identi-
fied and associated with 30–35% of cases of Brugada Syndrome, with nearly 20–25%
attributable to variants in SCN5A, meaning many cases remain undiagnosed genetically.
To evaluate the role of genetic variants in arrhythmogenic diseases and the utility of next-
generation sequencing, we applied this technology to resequence 28 main genes associ-
ated with arrhythmogenic disorders.
Materials and Methods
A cohort of 45 clinically diagnosed Brugada Syndrome patients classified as SCN5A-
negative was analyzed using next generation sequencing. Twenty-eight genes were rese-
quenced: AKAP9, ANK2, CACNA1C, CACNB2, CASQ2, CAV3, DSC2, DSG2, DSP,
GPD1L, HCN4, JUP, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNQ1,
NOS1AP, PKP2, RYR2, SCN1B, SCN3B, SCN4B, SCN5A, SNTA1, and TMEM43. A total of
85 clinically evaluated relatives were also genetically analyzed to ascertain familial
segregation.
Results and Discussion
Twenty-two patients carried 30 rare genetic variants in 12 genes, only 4 of which were previ-
ously associated with Brugada Syndrome. Neither insertion/deletion nor copy number varia-
tion were detected. We identified genetic variants in novel candidate genes potentially
associated to Brugada Syndrome. These include: 4 genetic variations in AKAP9 including a
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de novo genetic variation in 3 positive cases; 5 genetic variations in ANK2 detected in 4
cases; variations in KCNJ2 together with CASQ2 in 1 case; genetic variations in RYR2,
including a de novo genetic variation and desmosomal proteins encoding genes including
DSG2, DSP and JUP, detected in 3 of the cases. Larger gene panels or whole exome
sequencing should be considered to identify novel genes associated to Brugada Syndrome.
However, application of approaches such as whole exome sequencing would difficult the
interpretation for clinical purposes due to the large amount of data generated. The identifica-
tion of these genetic variants opens new perspectives on the implications of genetic back-
ground in the arrhythmogenic substrate for research purposes.
Conclusions
As a paradigm for other arrhythmogenic diseases and for unexplained sudden death, our
data show that clinical genetic diagnosis is justified in a family perspective for confirmation
of genetic causality. In the era of personalized medicine using high-throughput tools, clinical
decision-making is increasingly complex.
Introduction
In the last 20 years, the advent of advanced genetics has enabled rapid progress in the field of
inherited arrhythmogenic diseases associated with sudden cardiac death (SCD). In addition,
the genetic data have been rapidly translated into the clinical field, to be used in diagnostic, risk
stratification, and therapeutic strategies. Although genetics has been advocated as a tool to be
interpreted in the context of the clinical phenotype as a complementary test, in the field of
arrhythmogenic diseases genetics is emerging as a diagnostic tool in itself, providing a clue to
unexplained death. Herein, genetics is not a complement, but a substitute for the unsuccessful
clinical and forensic investigation [1]. Thus, in recent years we have moved from the use of
genetics to confirm a known disease, to the use of genetics to diagnose an unknown disease.
The recent developments in massively parallel sequencing (next-generation sequencing,
NGS) have provided access to thorough genetic screening. This technology is rapidly transi-
tioning to clinical practice, adding a new level of complexity to patient diagnosis and care. NGS
allows a fast and cost-effective approach for the genetic screening of a large panel of genes, rep-
resenting an ambitious strategy compared with Sanger sequencing. When combined with
inquiry into large-scale international genetic databases, NGS allows the scientific community
to acquire deeper spectra of the genetic variants contributing to specific phenotypes. However,
its use in clinical diagnosis remains a challenge due to the large amount of genetic information
that has to be interpreted to evaluate its pathological relevance.
NGS is beginning to be applied to arrhythmogenic diseases like Brugada syndrome (BrS).
The BrS is a rare, inherited arrhythmogenic disorder characterized by the presence of ST-seg-
ment elevation in the right precordial leads (V1 to V3), referred to as electrocardiogram (ECG)
type I. BrS causes SCD in the structurally normal heart, and affects predominantly men during
the third and fourth decade of life. Although the disease has classically been described as a pri-
mary electrical disorder involving the sodium channel and leading to the characteristic ECG, it
has been proposed that BrS may actually encompass a heterogeneous group of disorders with a
variety of genetic and clinical phenotypes. Currently, the major genetic contribution to BrS is
variation in the SCN5A gene, which represents 20_25% of all clinically diagnosed BrS cases.
Next-Generation Sequencing in Brugada Syndrome
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Another 15 genes have been associated with the disease, but together represent only about
5_10% of BrS cases [2]. Thus, close to 70% of BrS cases remain unexplained after comprehen-
sive genetic analysis of all previously associated genes. Current guidelines recommend to genet-
ically screening restricted to the SCN5A gene as the most resolute and cost-effective strategy
for genetic diagnosis of Brugada Syndrome affected patients [3][4]
To evaluate the role of genetic variants in arrhythmogenic diseases, we used NGS technol-
ogy to resequence 28 main genes associated with arrhythmogenic SCD in a cohort of BrS
patients. The results allow us to assess the value of this approach in confirming a diagnosis of a
clear clinical phenotype and also to draw conclusions on its potential value in forensic investi-
gation of patients with unexplained SCD.
Materials and Methods
Patient recruitment
We retrospectively recruited a total of 45 samples/clinical histories of adult patients clinically
diagnosed with BrS in a multicenter effort. These samples serve as the index case in each family.
All index cases included in the study were negative for pathogenic genetic variants in SCN5A
(see below). Informed consent for all samples was obtained in accordance with local institu-
tional review board guidelines of the Hospital Josep Trueta (Girona, Spain) and conforms to
the principles outlined in the Declaration of Helsinki. The project was approved by the local
review board (Hospital Josep Trueta-Girona). All patients and relatives signed their written
consent for research purposes before participation in this study. The diagnosis of BrS was
accepted when the patients showed an ECG type 1 (basally or after the administration of intra-
venous sodium channel blockers) in conjunction with at least one clinical criterion, reflecting
the occurrence of documented ventricular arrhythmia, family history (of SCD or BrS), and/or
symptoms secondary to arrhythmia. Structural heart disease was ruled out in all participating
individuals. S2 Fig and S3 Fig show two examples of ECG type 1 observed in two of the cases
included at the study.
Target enrichment: Custom resequencing panel
At the moment of the study, we had genetically analyzed a total of 63 individuals for SCN5A by
conventional Sanger sequencing: 18 of them resulted genetically positive for SCN5A (29% of
the cases) and the remaining 45 cases (71% of the cases) remained genetically negative. These
percentages are in agreement with data described in the literature and guidelines. In all these
45 samples, neither pathogenic nor potentially pathogenic variations were detected after Sanger
sequencing of SCN5A. All 45 BrS cases were genetically evaluated by means of target resequen-
cing of exonic, UTR, and intron-exon boundary regions of 28 core genes related to SCD,
included in a panel of massively parallel sequencing in SOLID 4 platform (Life Technologies
Waltham, MA USA). This panel includes AKAP9, ANK2, CACNA1C, CACNB2, CASQ2,
CAV3, DSC2, DSG2, DSP, GPD1L, HCN4, JUP, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2,
KCNJ5, KCNQ1, NOS1AP, PKP2, RYR2, SCN1B, SCN3B, SCN4B, SCN5A, SNTA1, and
TMEM43. We included genes associated with cardiac channelopathies as well as genes associ-
ated with arrhythmogenic right ventricular cardiomyopathy (ARVC), a disease difficult to
diagnose in its incipient forms even with powerful imaging techniques (Table 1).
The custom design of the Resequencing Panel is explained in S1 Methods. The 28 genes
were enriched using SureSelect Custom Target Enrichment System kit (Agilent Technologies,
Santa Clara_CA USA) following manufacturing protocol "SureSelect Target Enrichment Sys-
tem for SOLiD Fragment and Paired-End Sequencing version 1.3.” (See S1 Methods for custom
Next-Generation Sequencing in Brugada Syndrome
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design of the resequencing panel and the bioinformatics pipeline explanation and S1 Fig for
sequencing statistics)
The median percentage of reads on target was 46% for all 45 samples (ranging from 43% to
52%). The median coverage was 129x (ranging from 100x to 179x), and the 25th, 75th, and
95th percentiles were 83x, 216x, and 469x, respectively. (See S1, S2 and S3 Tables)
Variant validation and familial segregation study
Potential pathogenic rare variants with a MAF (minor allele frequency) under 1% were con-
sulted in locus-specific databases that included dbSNP [5], Ensembl genome browser [6], the
1000 Genomes Project [7], and EVS (Exome Variant Server, NHLBI GO Exome Sequencing
Project _ESP).
All genetic variants detected in the index cases were validated by conventional Sanger
sequencing. Previously published function-affecting variants as well as potential pathogenic
genetic variants were also analyzed in a total of 85 relatives by direct sequencing of those geno-
mic positions.
Table 1. Specific Ensemble isoforms and RefSeq codes included in the target resequencing custom panel. The design interrogates 191.12 Kb of
enriched genomic regions.
Gene ID Ensembl Transcript ID RefSeq n Exons Associated with BrS (%)
AKAP9 ENST00000356239 NM_005751 50 No
ANK2 ENST00000357077 NM_001148 46 No
CACNA1C ENST00000347598 NM_001129827 47 Yes (<5%)
CACNB2 ENST00000396576 NM_000724 13 Yes (<5%)
CASQ2 ENST00000261448 NM_001232 11 No
CAV3 ENST00000343849 NM_033337 2 No
DSC2 ENST00000280904 NM_024422 16 No
DSG2 ENST00000261590 NM_001943 15 No
DSP ENST00000379802 NM_004415 24 No
GPD1L ENST00000282541 NM_015141 8 Yes (<5%)
HCN4 ENST00000261917 NM_005477 8 Yes (<5%)
JUP ENST00000393931 NM_002230 14 No
KCNE1 ENST00000337385 NM_001270402;NM_001270403 3 No
KCNE2 ENST00000290310 NM_172201 2 No
KCNE3 ENST00000310128 NM_005472 3 Yes (<5%)
KCNH2 ENST00000262186 NM_000238 15 No
KCNJ2 ENST00000243457 NM_000891 2 No
KCNJ5 ENST00000338350 NM_000890 4 No
KCNQ1 ENST00000155840 NM_000218 16 No
NOS1AP ENST00000361897 NM_001164757 10 No
PKP2 ENST00000070846 NM_004572 14 Yes (<5%)
RYR2 ENST00000366574 NM_001035 105 No
SCN1B ENST00000415950 NM_199037 3 Yes (<5%)
SCN3B ENST00000392770 NM_018400 6 Yes (<5%)
SCN4B ENST00000324727 NM_174934 5 No
SCN5A ENST00000333535 NM_198056 28 Yes (20–25%)
SNTA1 ENST00000217381 NM_003098 8 No
TMEM43 ENST00000306077 NM_024334 12 No
doi:10.1371/journal.pone.0133037.t001
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In silico analysis of pathogenicity of rare nonsynonymous variants was performed with Con-
del Analysis [8] Mutation Taster (http://www.mutationtaster.org/), Polyphen (http://genetics.
bwh.harvard.edu/pph2/), and Provean (http://provean.jcvi.org/) (Table 2 and S1 Methods).
Data related to genetic variants detected in the study were submitted to the Leiden Open Varia-
tion Database 3.0 (URL http://www.lovd.nl/3.0/home) (Table 2). We have recently published a
restrictive score to consider the potential pathogenicity of a genetic variant for clinical assess-
ment [9]. This score was applied to the variants presented in this article (Table 2)
Results and Discussion
Clinical profiles
Our cohort included 45 families (130 individuals, 45 index cases plus 85 relatives). The average
age at the time of diagnosis of our index cases was 43.5 ± 14.83 years old; 31/45 (68.9%) were
males. Basal type 1 ECG was present in 27/45 (60%), and the remaining cases showed positive
ECG after drug test (flecainide, ajmaline, or procainamide). Of all index cases, 22/45 (55.6%)
had a previous clinical history of BrS in the family, and 19/45 (42.2%) had suffered previous
syncope, seizures, or nocturnal agonal respiration. Familial history of SCD occurred in 19/45
(42.2%) of our families. All the individuals under genetic analysis were clinically evaluated
using the same diagnostic procedures following international guidelines.
Genetic results
Thirty genetic variants, all of them in exonic regions of 12 genes, were detected in the heterozy-
gous state in 22 index cases (Table 3). In the remaining 23 cases, no potentially pathogenic vari-
ation was identified. The average age of our 22 index cases was 46.09±13.89 years old, with 14
(63.6%) being male. Fourteen index cases showed a BrS basal type 1 ECG. Clinical data are
shown in S4 Table _Clinical and familial information.
Segregation studies
After segregation and bioinformatic analyses, several potentially pathogenic rare variants were
identified in the 22 cases. These variants would be labeled as potentially causative in the event
of a screening performed in the single individual, victim of a cardiac arrest, or as part of the
forensic investigation of unexplained sudden death. Multiple genetic variants were detected in
6 cases (Table 2). Clinical data and family segregation are summarized in S4 Table. Family ped-
igrees are shown in Fig 1 to Fig 12. These figures show the phenotype of relatives as positive or
negative for BrS diagnosis. Clinical information of relatives is essential information to ascertain
the pathogenicity of the genetic variant that was detected in each index case after NGS. Taking
these data into account, we proceeded to divide the groups into three main classes according to
segregation variable:
Figs 1–12 show Pedigrees for phenotype correlation analysis on samples in Group 1.
Group 1. Positive segregation (see Fig 1 to Fig 12, S4 Table and Table 2 for segregation
results, familial clinical history and rare variant report and classification). Incomplete pene-
trance pattern of the detected variants is also considered into this first group. This group
includes 12 cases.
In the first 6 cases, the detected genetic variation showed complete penetrance. In cases 1
and 2 (Figs 1 and 2) the segregation variant was detected in the ANK2 gene. In case 3, two vari-
ations, in CASQ2 and KCNJ2, correlate with the disease in this large family with a history of
SCD (Fig 3). In case 4 the variant was detected inHCN4 (Fig 4). In case 5, the variant was
detected in JUP (Fig 5). Case 6 showed a novel de novo variation in the RyR2 gene (Fig 6). In
Next-Generation Sequencing in Brugada Syndrome
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Table 2. Report of rare variants detected. NA: DNA not available from relatives. IP: Incomplete penetrance. CM: Human gene variation database code.
MAF: Minor allele frequency in the NHLBI Exome Sequencing Project (ESP). LOVD ID: Submission ID on Leiden Open Variation Database. EA: European
American population. AA: African American population. Last revised January 2015. Predictors: C: Condel; MT: Mutation Taster; PPH2: Polyphen; Prov: Pro-
vean. N:N eutral; D: Deleterious; P: Polymorphism; DC: Disease causing; B: Benign; PD: Possibly_Damaging pathogenicity score based in Campuzano
et al. score [9] and applied to BrS. VUS: Variant of uncertain significance.
Group Index case
#LOVD ID


















1 #00028976 ANK2 c.8843C>G (p.
(Ala2948Gly))
rs138438183 0.0349 0.0227 0.0308 0.003 N/P/B/N Yes VUS




0.2326 0.6355 0.3691 0.084 N /P/B/N No Benign
2#00028977 ANK2 c.7132G>A (p.
(Glu2378Lys))
rs141191319 0.3488 0.0227 0.2384 0.003 N/P/B/N No Benign
2#00028977 ANK2 c.7334A>G (p.
(Asp2445Gly))
- 0.724 D/DC/PD/D Yes VUS
2#00028977 AKAP9 c.5246T>C (p.
(Ile1749Thr))
rs150016098 0.0465 0.0227 0.0384 0.950 D/DC/PD/D No Benign
3 #00028978 CASQ2 c.1148A>G (p.
(Asp383Gly))
rs397516640 - - - 0.01 N/P/B/D Yes VUS
3 #00028978 CACNB2 c.1511C>T (p.
(Thr504Ile))
rs143326262 0.2093 0.0227 0.1461 0.011 N/DC/PD/N No Benign




0.2326 0.6355 0.3691 0.084 N/P/B/N No Benign
3 #00028978 KCNJ2 c.532G>A (p.
(Ala178Thr))
- 0.005 N/DC/PD/N Yes VUS
4 #00028979 HCN4 c.3577G>C (p.
(Glu1193Gln))
rs200507617 0.0233 0 0.0154 0.709 D/DC/B/N Yes VUS
5 #00028980 JUP c.475G>T (p.
(Val159Leu))
- 0.019 N/DC/PD/D Yes VUS
6 #00028981 RYR2 c.3803T>C (p.
(Ile1268Thr))
De novo 0.508 D/DC/B/D Yes VUS
7 #00028982 AKAP9 c.3827G>A (p.
(Arg1276Gln))
rs146797353 0.8856 0.318 0.6932 0.007 N/P/B/N IP VUS
7 #00028982 AKAP9 c.8573A>G (p.
(Tyr2858Cys))
De novo 0.007 N/P/B/D IP VUS
8 #00028983 AKAP9 c.8656A>G (p.
(Ile2886Val))
rs143283097 0.035 0 0.0231 0.003 N/P/B/N IP VUS
9 #00028984 ANK2 c.3914G>A (p.
(Arg1305Gln))
- 0.981 D/DC/PD/N IP VUS
9 #00028984 PKP2 c.1781T>C (p.
(Ile594Thr))
- 0.974 D /DC/PD/D No Benign
10 #00028985 DSP c.1150G>C (p.
Glu384Gln)
- 0.766 D/DC/PD/N IP VUS
11 #00028986 DSP c.5218G>A (p.
(Glu1740Lys))
rs142885240 0.1279 0.0227 0.0923 0.408 N/P/PD/N IP VUS
12 #00028987 PKP2 c.2504A>G (p.
(Lys835Arg))
rs372729739 0.0116 0 0.0077 0.254 N/DC/PD/N IP VUS
Group
2
13 #00028988 ANK2 c.5758G>A (p.
(Gly1920Arg))
rs140189724 0.0233 0.0227 0.0231 0.001 N/P/PD/N NA VUS
14 #00028996 CACNA1C c.5875G>C (p.
Gly1959Arg)
- 0.003 N/DC/PD/N NA VUS
15 #00028990 DSG2 c.3209C>T (p.
(Thr1070Met))
rs149617776 0.0604 0.0265 0.0498 0.019 N/P/B/N NA VUS









- 0.949 D/DC/PD/N NA VUS
(Continued)
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these 6 cases, 6 additional potentially functional affecting variants were also identified. How-
ever, those 6 variations did not segregate with the pathology in the family.
The remaining 6 cases in this first group showed an incomplete penetrance pattern of inher-
itance (Table 2). In two cases, 7 and 8 (Figs 7 and 8), the genetic variation was detected in
AKAP9. Case 9 (Fig 9) had two genetic variants, in ANK2 and PKP2. The remaining three cases
had variants in DSP and PKP2 (Fig 10 to Fig 12).
Group 2. Unclear segregation (see Table 2 for rare variant report and classification).
The second group includes those cases in which DNA was not available for genetic rese-
quencing from relatives, therefore prohibiting ascertainment of segregation. This group
comprises 5 cases (Table 2), in which 6 variations were detected in 6 different genes.
In case 13 the genetic variation detected in ANK2 c.5758G>A; (p.(Gly1920Arg)) was previ-
ously catalogued as rs140189724 and predicted as neutral. Family history included a brother
affected with BrS. Case 14 was a carrier of a previously undescribed genetic variation in CAC-
NA1C c.5875G>C; (p.(Gly1959Arg)), predicted as neutral. He was a 33-year-old man diag-
























rs149542398 0.0465 0.0227 0.0384 0.732 D/P/B/N NA VUS
Group
3
18 #00028995 ANK2 c.2945G>A (p.
(Arg982Gln))
- 0.981 D/DC/PD/D No Benign
19 #00028997 CACNA1C c.2449C>T (p.
(Pro817Ser))
rs112532048 0.4679 0.0738 0.3387 0.004 N/DC/PD/N No Benign
20 #00028998 CACNB2 c.1925T>C (p.
(Ile642Thr))
- 0.02 N/DC/B/N No Benign
21 #00028999 DSG2 c.1003A>G (p.
(Thr335Ala))
rs191564916 0.061 0 0.0419 0.287 N/P/PD/N No Benign




0.7881 0.2403 0.617 0.867 D /DC/B/D No Benign
doi:10.1371/journal.pone.0133037.t002
Table 3. Relationship of genes in which rare variation was detected. Segregation study outcomes are shown. BrS: Brugada syndrome, LQTS: Long QT
syndrome, ATS: Anderson-Tawil syndrome. CPVT: catecholaminergic polymorphic right ventricular tachycardia. SSS: Sick Sinus syndrome. *Cerrone et al.
recently defined the co-existence of clinical BrS and genetic variations in PKP2 [10].
Gene Ensembl Isoform RefSeq Positive segregation study Previously associated with BrS Associated disease
AKAP9 ENST00000356239 NM_005751 Yes No LQTS11
ANK2 ENST00000357077 NM_001148 Yes No LQTS4
CACNA1C ENST00000347598 NM_001129827 Unknown Yes LQT8, ATS1
CACNB2 ENST00000324631 NM_000724 No Yes BrS
CASQ2 ENST00000261448 NM_001232 Yes No CPVT
DSG2 ENST00000261590 NM_001943 No No Cardiomyopathy
DSP ENST00000379802 NM_004415 Yes No Cardiomyopathy
HCN4 ENST00000261917 NM_005477 Yes Yes SSS
JUP ENST00000562805 NM_002230 Yes No Cardiomyopathy
KCNJ2 ENST00000243457 NM_000891 Yes No CPVT
PKP2 ENST00000070846 NM_004572 Yes Yes* Cardiomyopathy
RYR2 ENST00000366574 NM_001035 Yes No CPVT, LQTS
doi:10.1371/journal.pone.0133037.t003
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SCD. Case 15, a 40-year-old man diagnosed with a positive basal ECG, carried the genetic
variation in DSG2 c.3209C>T (p.(Thr1070Met)); rs149617776, which is predicted neutral.
Family history included a 30-year-old brother who died suddenly. Case 16, whose father
died suddenly, was a 41-year-old man with the DSP variant c.8455A>C (p.(Met2819Leu));
rs138329459 CM132698) [12], which is predicted as neutral. Two variations, RyR2 c.5056C>T
(p.(Leu1686Phe)), which is novel, and PKP2 c.302G>A (p.(Arg101His)); rs149542398, were
Fig 1. Case-Family 1. Segregation of the ANK2 c.8843C>G (p.(Ala2948Gly)) (rs138438183) and lack of
segregation on PKP2 c.1577C>T (p.(Thr526Met)) (rs146882581_CM113820[11]), rare variant also detected
in case 3. Case 1 (II.1), 47-year-old woman. Individuals (II.2 and II.3) were also diagnosed with BrS both with
previous syncope and one of them (II.2) showed a positive ajmaline test.
doi:10.1371/journal.pone.0133037.g001
Fig 2. Case-Family 2. Positive segregation of ANK2 c.7334A>G (p.Asp2445Gly) and lack of segregation on
ANK2 c.7132G>A (p.(Glu2378Lys)) (rs141191319) and AKAP9 c.5246T>C (p.(Ile1749Thr)) (rs150016098).
The family history includes two brothers diagnosed at an age of 36 and 34 (III.2 and III.3, respectively), his
asymptomatic sister (III.4), and his mother (II.2) affected by BrS. Individual III.2 showed a positive ECG
pattern and a positive EPS although remaining asymptomatic. An ICD was implanted. Individual III.3 had a
positive ajmaline test. Their previously asymptomatic mother (II.2) showed a positive EPS and an ICD was
implanted.
doi:10.1371/journal.pone.0133037.g002
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detected in case 17, a 46-year-old man with a positive ECG at baseline. Both were predicted as
deleterious. Family history included two uncles who died suddenly.
Group 3. Negative segregation (see Table 2 for rare variant report and classification).
The third group includes 5 cases in which the variations detected did not segregate with the
phenotype in the available family members (Table 2); these cases therefore remain undiag-
nosed genetically. Interestingly, the variants detected were predicted as pathogenic by infor-
matics tools.
In case 18 the variation ANK2 c.2945G>A (p.(Arg982Gln)), not previously described, was
identified and was predicted deleterious. Two of the case’s four children were also diagnosed
with BrS but did not carry the detected variant. Case 19 belonged to a large family with history
of sudden death. CACNA1C c.2449C>T (p.(Pro817Ser)); rs112532048, considered neutral,
was detected in 13 relatives. Two affected individuals did not carry the genetic variation. Case
20 carried the variant CACNB2 c.1925T>C (p.(Ile642Thr)), considered neutral. One of the
daughters was affected with BrS but did not carry the genetic variant, thus indicating the varia-
tion was not causative of the pathology. Case 21 carried DSG2 c.1003A>G (p.(Thr335Ala));
rs191564916, considered neutral. He had a positive basal ECG and syncope. His father and one
brother showed a positive flecainide test but did not carry the variation. Case 22 carried the
genetic variation DSG2 c.473T>G (p.(Val158Gly)); rs191143292_CM070921, considered dele-
terious. He was a 38-year-old man diagnosed with BrS after a positive basal ECG. Family
Fig 3. Case-Family 3. CASQ2 c.1148A>G (p.(Asp383Gly)) and KCNJ2 c.532G>A (p.(Ala178Thr))
segregation is shown. Also the lack of segregation ofCACNB2 c.1511C>T (p.(Thr504Ile)) (rs143326262) and
PKP2 c.1577C>T (p.(Thr526Met)) (rs146882581 also detected in Case 1). Individual I.1 died at age 65
because of chronic cardiovascular disease. Individual I.2 died at age 76 because of congestive heart failure.
The second generation of this family includes 9 siblings (II.1-II.9), 5 of them-all male- died suddenly at ages
between 42 and 53 years (II.1-II.5) and also a brother who died stillborn (II.9). Two siblings (II.7 and II.8), both
female, died from other causes. The last sibling, a 91-year-old woman (II.6), is still alive and was diagnosed with
atrial fibrillation (AF) at a young age. The third generation includes our index case (III.6), a 66-year-old man who
was diagnosed with AF at 18 years of age. Notably, one SIDS case (III.4) was recorded in this generation.
Clinical history and evaluation of the index case includes syncope at age 54, BrS pattern at ECG, and positive
EPS, leading to an ICD implantation. His offspring are a 39-year-old asymptomatic daughter (IV.1) with
negative EPS and procainamide test, a 20-year-old man (IV.2) who died suddenly, and a 31-year-old man
(IV.3) diagnosed with AF, with negative procainamide test, positive EPS, and previously asymptomatic.
doi:10.1371/journal.pone.0133037.g003
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history included sudden death of his father and brother, as well as positive flecainide test in
another brother, who carried the same genetic variant. His two sons were also diagnosed with
BrS, but only one of them carried the variant.
In recent years, some compendiums focusing on the genetics of BrS have been published.
These studies performed Sanger sequencing of known BrS-related genes and showed that 20 to
Fig 4. Case-Family 4. Positive segregation ofHCN4 c.3577G>C (p.(Glu1193Gln)) (rs200507617) with the
pathology in the family. Individual II.1 is a symptomatic 70-year-old man (II.1) who showed a pathologic BrS
ECG pattern and positive EPS, and had an ICD implanted. The genetic variant, predicted as deleterious, was
absent in his healthy brother (II.2), with a non-pathological ECG.
doi:10.1371/journal.pone.0133037.g004
Fig 5. Case-Family 5. Positive segregation of JUP c.475G>T (p.(Val159Leu)) with the pathology in the
family. This variant was previously considered as a pathogenic variant (CM1010258). Case II.1 is a 30-year-
old man with a positive basal BrS ECG, syncope, and positive EPS. His brother (II.2), a 26-year-old man
diagnosed with a positive ECG after flecainide test, and a positive EPS was also a carrier of the detected
variation. Both relatives carry an ICD. Family history includes BrS diagnosed in their father (I.1).
doi:10.1371/journal.pone.0133037.g005
Next-Generation Sequencing in Brugada Syndrome
PLOSONE | DOI:10.1371/journal.pone.0133037 July 31, 2015 10 / 21
25% of BrS patients carry a pathogenic variation in the SCN5A gene. However, nearly 70% of
BrS patients remain without genetic cause after genetic analysis. Accordingly, the Canadian
Cardiovascular Society/Canadian Heart Rhythm Society expert consensus statement suggested
genetic testing only of the SCN5A gene for any patient diagnosed with BrS. This consensus rec-
ommends that the genetic testing of minor BrS-associated genes should only be considered
under special circumstances, given the difficulty of drawing clinical conclusions from few
patients with these genetic defects and the low yield of genetic testing in these less prevalent
genes [3].
However, the development of high-throughput technologies allows the screening of large
sets of genes at once. Therefore, NGS technology is progressively being incorporated into clini-
cal diagnosis. To the best of our knowledge, our study is the first comprehensive genetic analy-
sis using NGS technology to identify genetic variants associated with BrS. Indeed, in our study,
NGS resequencing of individuals with BrS detected a total of 30 rare geneticmissense variants
in the heterozygous state; all were validated by conventional Sanger sequencing.
The study had three main purposes: 1. to determine genetic causality in patients with BrS
who did not carry a variation in SCN5A; 2. to assess the value of NGS technology and bioinfor-
matics tools in determining causality; and 3. to use these data to interpret genetic causality in
the event that these were cases of unexplained SCD. These objectives are critical to determining
whether there exists a role for NGS in the clinical diagnosis of sudden death, especially consid-
ering that the current recommended strategies to determine causality are not definitive: segre-
gation analyses may not always be possible, bioinformatics pathogenicity prediction may not
always be accurate, and functional analyses are never performed for clinical determination of
causality. The lack of this in vitro/in vivo analysis is the main limitation to determining the
score of pathogenicity. However, using NGS data, and accepting present limitations and pres-
ent knowledge, we have identified several variants potentially causative of BrS, based on low
prevalence in the general population.
Fig 6. Case-Family 6. Positive segregation of the de novo detected variant RYR2 c.3803T>C (p.
(Ile1268Thr)) with the pathology in the family. The index case (II.1) is a 48-year-old woman, previously
asymptomatic, with a positive flecainide test and negative EPS study. The variant was also detected in one of
her two daughters (III.1), clinically affected of BrS showing a positive ajmaline test. The second daughter
(III.2) was clinically unaffected.
doi:10.1371/journal.pone.0133037.g006
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ANK2
Previous studies demonstrated the role of ankyrin, especially ankyrin-G, in the sodium channel
trafficking that results in several life-threatening conditions including cardiac arrhythmias.
While ankyrin-G is required for the targeting of Nav1.5 to the cardiomyocyte intercalated disc,
ankyrin-B is required for targeting the Na+/Ca++ exchanger and Na+/K+ ATPase to transverse
tubule membranes in the heart. Interestingly, ankyrin-B knockout mice exhibit a delayed open-
ing of the sodium channel, although no evidence of an interaction between the sodium channel
and ankyrin-B has been reported so far. ANK2 (encoding ankyrin-B) was previously associated
with LQTS type 4, producing a loss-of-function effect. A total of 5 genetic variations in ANK2
were detected in 4 cases. Cases 1 and 2 had complete penetrance; in case 13 a segregation study
could not be completed as DNA was not available from relatives; and in case 18 the variant did
not segregate with the pathology in the family. The incidence of these rare variants implicates
Fig 7. Case-Family 7. Incomplete penetrance pattern of both variations in AKAP9 c.3827G>A (p.(Arg1276Gln)) (rs146797353) and the de novo detected
variant AKAP9 c.8573A>G (p.(Tyr 2858Cys)) in the family. The index case, II.1, is a 44-year-old man with a positive basal ECG, previously asymptomatic,
and positive EPS and flecainide test. No family history of SD was reported. The variant AKAP9 c.3827G>A (p.Arg1276Gln) was also detected in 4 more
relatives: his asymptomatic mother (I.2); one clinically-affected sister with a positive flecainide test (II.3); an asymptomatic brother with negative ajmaline test
(II.4); and an asymptomatic nephew (III.4). Familial segregation showed that the variant was absent in four clinically unaffected relatives: I.1, III.1, III.2, and
III.3. Additionally, the index case showed another de novo variant in AKAP9 c.8573A>G (p.(Tyr2858Cys)), also identified in his two asymptomatic children
(III.1 and III.2). This last variant, absent in the remaining available relatives, is also absent in the international databases.
doi:10.1371/journal.pone.0133037.g007
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ANK2 as a potential candidate gene in BrS. Further functional and molecular studies of the
detected variants should clarify the molecular mechanisms related to pathogenic variations in
the ANK2 gene that underlies a BrS phenotype [13–15].
Fig 8. Case Family 8. Incomplete penetrance pattern of AKAP9 c.8656A>G (p.(Ile2886Val)) (rs143283097)
in the family. Family history of sudden death was related. Individual III.3 is a 43-year-old woman previously
asymptomatic, with a negative basal ECG but positive procainamide test and EPS. The variant was detected
in her asymptomatic daughter (IV.4) and also in (III.2), clinically affected. Her asymptomatic brother (III.1) did
carry the variation. The asymptomatic nephew (IV.3) did not carry the variant.
doi:10.1371/journal.pone.0133037.g008
Fig 9. Case-Family 9. Incomplete penetrance pattern of ANK2 c.3914G>A (p.(Arg1305Gln)) and the lack of
penetrance of PKP2 c.1781T>C (p.(Ile594Thr)) in the family. Individual I.1 is a 74-year-old symptomatic man
with both a positive ajmaline test and EPS. His 51-year-old daughter (II.1) was also diagnosed with BrS,
showing a positive ajmaline test. Her 21-year-old granddaughter (III.1) is asymptomatic and had a negative
ajmaline test. p.Arg1305Gln was not previously described and is predicted deleterious. A second variant
considered deleterious, PKP2 (p.(Ile594Thr)), was detected in the index case (I.1), but was absent in II.1 and
III.1.
doi:10.1371/journal.pone.0133037.g009
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CASQ2
Homozygous variations in CASQ2 are associated with recessive forms of catecholaminergic
polymorphic ventricular tachycardia (CPVT), an inherited arrhythmogenic disorder associated
with SCD. However, CASQ2 was not previously associated with BrS. CASQ2 encodes calse-
questrin, which is located inside the sarcoplasmic reticulum (SR) and buffers the physiological
intra-SR calcium. In case 3, the genetic variant in CASQ2 was accompanied by a second variant,
in KCNJ2, which also segregated with the pathology. Variations in KCNJ2 are associated with
LQTS type 7 and short QT syndrome. A related gene, KCNJ8, has been associated with BrS,
though at present it appears that some of the variations are actually normal variants in the
Fig 10. Case-Family 10. Incomplete penetrance of DSP c.1150G>C (p.(Glu384Gln)). Individual II.3 is a
48-year-old woman clinically affected with BrS. It was also confirmed in two more relatives: both
asymptomatic sister and daughter (II.1 and III.3). The variant was absent in another sister and two daughters
and a son (II.2, III.1, III.4 and III.2). Family history includes SCD in a 12-year-old daughter (III.5).
doi:10.1371/journal.pone.0133037.g010
Fig 11. Case-Family 11. Incomplete penetrance of DSP c.5218G>A (p.(Glu1740Lys)) (rs142885240).
Individual II.2 is a 68-year-old woman, previously asymptomatic but with positive basal ECG and
procainamide test. An ICD was implanted. Her affected son (III.1) and two clinically asymptomatic sons (III.2
and III.4) also carry the same genetic variant. Her husband (II.1) and children (III.3 and III.6), also
asymptomatic, did not carry the variant.
doi:10.1371/journal.pone.0133037.g011
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general population. In addition, in this family, two members carry both genetic variations are
also clinically diagnosed for AF. This fact agrees with the pathogenic variations reported in the
KCNJ2 gene in patients diagnosed with AF [16],[17].
HCN4
HCN4 encodes the potassium/sodium hyperpolarization-activated cyclic nucleotide-gated
channel 4 and was previously associated with BrS. In the Human Gene Variation Database
(HGMD), 10 variations in HCN4 have been described, with just one of them associated with
BrS [18]. The variant we detected was previously reported but not classified for its pathogenic
effect. In silico database analysis predicted the variation rs200507617 as deleterious.
Desmosomal proteins
Although, historically, genes encoding desmosomal proteins have not been associated with
BrS, Cerrone et al. recently defined the co-existence of clinical BrS and genetic variations in
PKP2, which encodes the desmosomal protein plakophilin [10]. Desmosomal proteins, particu-
larly plakophilin and desmoglein, interact with Nav1.5, [19]. Indeed, a recent review proposed
that alterations in the “connexome” are the origin of BrS [20]. This interaction could be a possi-
ble explanation of the observed variation in genes encoding desmosomal proteins in BrS in
our study. We identified several variations in JUP, DSP, PKP2, and DSG2. Variants of these
desmosomal proteins are associated with ARVC and dilated cardiomyopathy (DCM), both
structural heart pathologies associated with SCD. In case 5 we detected the variant JUP p.
Val159Leu, previously associated with ARVC (CM1010258) [21]. Cases 21 and 22 carried a
genetic variant in DSG2. Although these did not segregate with the pathology, one of the varia-
tions, rs191143292, was already published as pathogenic and causal for ARVC [22]. These
genetic variations detected in our cohort should be further studied to clarify their role in BrS.
Fig 12. Case-family 12. Incomplete penetrance of PKP2 c.2504A>G (p.(Lys835Arg)) (rs372729739) in the
family. Individual II.1 is a 38-year-old woman who suffered several syncopes and showed positive ECG-Type
I after ajmaline test and had no family history of sudden death. Her son and daughter (III.1 and III.2) and two
brothers (II.3 and II.4), all asymptomatic, did not carry the genetic variant. The variant was identified in an
asymptomatic brother (II.2), and an affected sister (II.6) and child (III.5).
doi:10.1371/journal.pone.0133037.g012
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RYR2
Genetic variants in the RyR2 gene were also detected in our cohort. RyR2 encodes the ryano-
dine receptor 2. Variations in this gene have been associated with CPVT and LQTS. Arrhyth-
mia susceptibility in LQTS individuals may be due to two distinct Ca2+ mechanisms: the early
afterdepolarizations (EADs), which are driven by reactivation of the L-type calcium channels
during repolarization, and a mechanism that may occur during diastole (delayed afterdepolari-
zations, DAD) via Ca2+ cycling by altering the function of the cardiac RyR2 channel [23]. The
detected variation segregates in case 6, but in case 17 segregation could not be established. To
date, no association between BrS and this gene has been described, though calcium channels
have been associated with the disease [24].
Calcium channels
Several genetic variations in two calcium channel genes were identified in our samples. Two
variants were detected in CACNA1C, which encodes Cav 1.2. However, segregation analysis
was not available in case 14, and no segregation was shown in case 19. Similarly, the segrega-
tion study was negative in case 20 for the genetic variant in CACNB2. Although both genes
have been associated with BrS [24], analysis of variants did not clarify their pathogenic role in
BrS. Although calcium channels and their associated proteins have been proposed as candi-
dates for BrS pathogenesis, we cannot make any conclusion for their role following NGS and
segregation analysis of the detected variants.
AKAP9
Two cases showed genetic variations in AKAP9, both with incomplete penetrance. AKAP9
encodes Yotiao protein, associated with LQTS and having a critical contribution to Iks regula-
tion [25]. As other potassium channels, such Kv4.3, MiRP1, and MiRP2, have been associated
with BrS, similar mechanisms could underlie BrS in these cases.
De novo variants in RyR2 and AKAP9
Two de novo variations were identified; one in case 6, RyR2 p.I1268T/c.3803T>C, and one
in case 7, AKAP9 (p.(Tyr2858Cys)). The latter was detected together with AKAP9 (p.(Arg
1276Gln)). However, in case 7 this novel variation did not correlate with the pathology, as the
affected individual II.3 (Fig 8) did not carry the variation.
Only 3 of the 12 genes in which we have identified potentially pathogenic variations were
previously associated with BrS—four, considering the recently published data in PKP2 [10]. All
these genes are likely new candidate genes as all are already associated to arrhythmogenesis
and SCD. In addition, the in silico predictor tools together with the genetic variation frequency
in general population and, most importantly the segregation analysis in relatives make all these
genes, make these genes good candidate genes to further investigate their role in the genetic
substrate of BrS. These results need to be further evaluated in larger BrS cohorts to investigate
their function in BrS pathogenesis. The identified variants should be examined in cellular mod-
els to further confirm causality. The studies could provide novel mechanistic insights into BrS
and arrhythmogenesis.
With these data, we show that several other genes may potentially be causative of the dis-
ease, genes that had been previously associated with other arrhythmogenic diseases. As is well
known in these other arrhythmogenic diseases, most of the detected variants showed incom-
plete penetrance. The lack of phenotype in carriers does not preclude segregation, as there can
be latent phenotypes, differences in gender and age, or the presence of genetic modulators. In
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addition, several variants may be identified in these cases. The possible combination of multi-
ple variants could have an essential role in the variability in phenotype expression. Several
modifying genetic factors have been described in BrS, and some additional ones have been pro-
posed [26] [27]. Bezzina et al. described genetic variants that show a cumulative large effect on
BrS susceptibility [28]. As in other SCD-related syndromes, like LQTS, variation in the expres-
sivity related to several genetic variations has been described [29] [30].
Segregation, or lack thereof, was believed to provide a definite lack of association with cau-
sality. However, in recent years some data have questioned this for BrS. In some of the families,
clinically affected family members do not share the variation in SCN5A. Lack of segregation
may indicate either that this is not a causative variation or that it is a predisposing genetic fac-
tor, albeit weaker than once thought. Previous data show the lack of complete segregation of
SCN5A variations in some families [31], as well as the presence of induced ST elevation as the
first ECG alteration just before the SCD event [32]. This raises the hypothesis that the BrS ECG
could actually be an electrical pattern triggered by a genetic predisposition to electrical instabil-
ity, but which goes beyond pure Mendelian genetics. It is in this context that the data presented
here can be scientifically understood. It is unlikely that there is an additional presence of varia-
tions associated with other diseases in patients with BrS, given that these are such rare diseases.
The ECG pattern could be the result of combining either a strong genetic background (varia-
tion in SCN5A), or several minimal genetic alterations, with a certain structural makeup of the
right ventricle that predisposes to slowing of conduction.
Several new bioinformatics tools enable an approach to the level of pathogenicity, which
assesses, among other factors, the absence of the variation in the normal population as well as
the effect of the variation in the protein. The localization of a raremissense variant in a critical
area of the cardiac ion channel protein, or a truncating variation in major associated genes, are
supposed to be pathogenic [33]. In silico prediction tools are thought to be useful when they
show a deleterious score, but its value in neutral and benign scores seems less robust. In cases
included in group 3, Segregation analyses definitively indicated that the variants were not caus-
ative, but it remains to be seen if, in the future, they will be classified as genetic modulators of
the phenotype.
New minority genes had been recently associated with BrS (SCN2B, SCN10A, RANGRF,
SLMAP, ABCC9, KCNJ8, KCND3, KCNE5, CACNA2D1 and TRPM4). These genes were not
included when the resequencing panel was designed. Although the percentage of genetically
positive cases in those genes is low, these genes should be considered when re-designing rese-
quencing panel for genetic screening of BrS to get more data in several cohorts that support the
association of these genes with the disease. Of note, current recommendations on general
guidelines are still restricted to SCN5A. We can therefore hypothesize that in the clinical arena
whole exome sequencing in BrS patients could result even in more harm at the moment due to
the large amount of data generated and needed to be interpreted. However, in large well-char-
acterized families, the whole exome sequencing should be considered for research purposes.
An exhaustive bioinformatic analysis did not detect insertions/deletions or copy number
variations in our samples. This analysis was developed by using an in-house bioinformatics
pipeline (manuscript under construction).
Conclusions
In conclusion, this work highlights the challenges that we face in the diagnosis of unexplained
SCD. We have used BrS as a paradigm of unexplained sudden death in the structurally normal
heart. We show that the identification of a genetic defect in the victim is not equivalent to pro-
viding a clear diagnosis. The identified genetic defects have provided a potential diagnosis of
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BrS, LQTS, CPVT, and ARVC. Massively parallel sequencing confirms that it is not always pos-
sible to determine the phenotype from genetic data. The inclusion of functional analyses could
be determinant to assign a definite diagnosis, but this is not possible at the present rate of varia-
tion detection. Therefore, the introduction of NGS technology has led to more questions unan-
swered compared with the pre-NGS era. This was an expected challenge that always comes
about in these approaches when large lists of genes are interrogated. The sequencing process of
those genes gives huge amounts of data that had to be stored, analyzed and biologically and
clinically interpreted. Genetic diagnosis by means of NGS is still a challenge since its applica-
tion to clinical diagnosis requires first an international effort for better understanding of the
significance of the rare genetic variations detected. One of the main objectives of the present
work is to evaluate the applicability of NGS to clinical (and forensic) diagnosis. After the analy-
sis of our results, this objective appears difficult to assess and only possible from a familiar per-
spective. However, even with the availability of relatives to enlarge the segregation study, the
genetic diagnosis is still difficult to estimate. Detection of novel, presumed disease causing, rare
genetic variants in several genes that were not previously associated to BrS are logical conse-
quence of the study. Association of those genes to the disease need to be further evaluated by
means of functional studies and replicated in different cohorts before being considered as
genetically conclusive for clinical diagnosis. Several reason support that the genes described
above should be considered candidate genes for research purposes for better understanding of
genetics mechanisms underlying. These reason iclude the role of the proteins encoded by these
genes, the low frequency or their absence of the genetic variations in general populations, their
potential pathogenicity evaluated in silico and when possible, with the segregation analysis per-
formed. These facts suggest a pathogenic role of the genetic variation detected. However, they
are considered as VUS after applying the algorithm, mainly due to the lack of functional studies
and genotype-phenotype analysis in different familiar cohorts. It is common that rare variants
remains as VUS. This observation agrees with the characteristic of pathologies with incomplete
penetrance and variable expressivity observed. To ascertain the pathogenic role of the detected
variations, genotype-phenotype correlations are required in other familiar cohorts as part of
international efforts to further increase understanding of the mutation spectrum underlying
BrS. In this direction, GWAS analysis (ya existen) from international consortiums including
several BrS cohorts had been published and also are nowadays being developed. These results
would result clarifying and open new research perspectives to be evaluated,
Technological progress has been more rapid than our capacity to apply it in the clinical
arena. The genetic architecture in terms of genes involved, rare and common genetic variants,
and modifying factors creates a complex decision network that can only be unraveled by careful
clinical and genetic interpretation in a family context. This reinforces the need for accurate and
thorough familial investigation, but also the importance of having the data handled by experts
in the field, so as to understand the value but also the limitations of these NGS tests.
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